• Product NameCanertinib (CI-1033)
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivityCanertinib (CI-1033) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.
• Target NameEGFR inhibitor
• CAS No. 267243-28-7
• Calculated MW 485.94
• Formulation C24H25ClFN5O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1
  Pathways:Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
  Receptor:EGFR; HER2/ErbB2
  Boling pt:
  Melting pt:
  Solubility:DMSO:2 mg/mL (4.11 mM)Ethanol:9 mg/mL (18.52 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Smaill JB et al. J Med Chem. 2000; 43(7): 1380-1397.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting